A detailed history of Susquehanna Fundamental Investments, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Susquehanna Fundamental Investments, LLC holds 241,874 shares of EXEL stock, worth $8.05 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
241,874
Previous 459,596 47.37%
Holding current value
$8.05 Million
Previous $10.9 Billion 50.17%
% of portfolio
0.13%
Previous 0.51%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$20.34 - $23.73 $4.43 Million - $5.17 Million
-217,722 Reduced 47.37%
241,874 $5.43 Billion
Q1 2024

May 07, 2024

BUY
$20.17 - $23.93 $9.27 Million - $11 Million
459,596 New
459,596 $10.9 Billion
Q3 2022

Nov 14, 2022

SELL
$15.68 - $22.27 $474,210 - $673,511
-30,243 Reduced 20.21%
119,394 $1.87 Million
Q1 2022

May 16, 2022

BUY
$17.03 - $22.67 $802,351 - $1.07 Million
47,114 Added 45.95%
149,637 $3.39 Million
Q4 2021

Feb 14, 2022

SELL
$15.84 - $21.88 $83,255 - $115,001
-5,256 Reduced 4.88%
102,523 $1.87 Million
Q3 2021

Nov 15, 2021

BUY
$16.3 - $21.14 $112,388 - $145,760
6,895 Added 6.83%
107,779 $2.28 Million
Q2 2021

Aug 11, 2021

SELL
$17.95 - $25.56 $2.32 Million - $3.3 Million
-129,207 Reduced 56.15%
100,884 $1.84 Million
Q1 2021

May 17, 2021

BUY
$20.53 - $25.22 $3.32 Million - $4.08 Million
161,825 Added 237.05%
230,091 $5.2 Million
Q4 2020

Feb 16, 2021

BUY
$18.39 - $24.8 $1.26 Million - $1.69 Million
68,266 New
68,266 $1.37 Million
Q3 2020

Nov 16, 2020

SELL
$20.67 - $26.94 $221,169 - $288,258
-10,700 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$16.46 - $27.42 $176,122 - $293,394
10,700 New
10,700 $254,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Susquehanna Fundamental Investments, LLC Portfolio

Follow Susquehanna Fundamental Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.